Biotransformation and molecular docking studies of aromatase inhibitors

Glenroy Martin*, Javier Narvaez, Rachel Bulmer, Marcus Durrant

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)
    14 Downloads (Pure)

    Abstract

    Bioconversion of the aromatase inhibitor formestane (4-hydroxyandrost-4-ene-3,17-dione) by the fungus Rhizopus oryzae ATCC 11145 resulted in a new minor metabolite 3,5α-dihydroxyandrost-2-ene-4,17-dione and the known 4β,5α-dihydroxyandrostane-4,17-dione as the major product. The structural elucidation and bioactivities of these metabolites are reported herein. Molecular modeling studies of the interactions between these metabolites and the aromatase protein indicated that acidic (D309), basic (R115), polar (T310), aromatic (F134, F221, and W224), and non-polar (I133, I305, A306, V369, V370, L372, V373, M374, and L477) amino acid residues contribute important interactions with the steroidal substrates. These combined experimental and theoretical studies provide fresh insights for the further development of more potent aromatase inhibitors.
    Original languageEnglish
    Pages (from-to)95-102
    JournalSteroids
    Volume113
    Early online date12 Jul 2016
    DOIs
    Publication statusPublished - 1 Sept 2016

    Keywords

    • Aromatase inhibitor
    • Molecular docking
    • Rhizopus oryzae
    • Formestane
    • Biotransformation
    • Cytochrome P450 monooxygenase

    Fingerprint

    Dive into the research topics of 'Biotransformation and molecular docking studies of aromatase inhibitors'. Together they form a unique fingerprint.

    Cite this